Diabetic foot (DF) is one of the most severe complications of diabetes that significantly
reduces the quality of life and survival of patients. Besides firmly established risk factors, novel
data indicate that alterations in lipid metabolism might also be implicated in the development and
progression of DF. Diabetic dyslipidemia is characterized by the atherogenic triad, consisting of
increased triglycerides (TG), decreased high-density lipoprotein cholesterol (HDL-C) levels and
the presence of small, dense low-density lipoprotein (LDL) particles. Accumulating evidence
suggests that profound hypertriglyceridemia and HDL-C reduction are common findings in
patients with diabetic neuropathy and significantly contribute to an increased risk for DF,
amputation and mortality. Small, dense LDL particles play an important role in the development
of cardiovascular complications of diabetes, but their clinical importance in patients with DF
remains to be established. In this paper, we ...will discuss the significance of standard and novel
lipid biomarker determination in the assessment of the risk for the development and progression
of DF.
Dijabetesno stopalo (DS) je hronična komplikacija dijabetesa koja značajno pogoršava kvalitet života pacijenata i doprinosi visokoj stopi smrtnosti. Noviji podaci ukazuju da i poremećaj metabolizma lipida može biti uključen u razvoj i progresiju DS. Dislipidemija u dijabetesu se odlikuje postojanjem tzv. aterogene trijade, koju čine povišena koncentracija triglicerida (TG), snižena koncentracija HDL-holesterola (HDL-h) i prisustvo malih, gustih LDL čestica. U nedavno sprovedenim studijama utvrđeno je da izražena hipertrigliceridemija i snižena koncentracija HDL-h, koje su najčešće prisutne kod pacijenata sa dijabetesnom neuropatijom, dodatno doprinose razvoju DS, amputaciji i mortalitetu. Poznato je da male, guste LDL čestice imaju važnu ulogu u razvoju kardiovaskularnih komplikacija u dijabetesu, ali je značaj ovih čestica kod pacijenata sa DS još uvek nedovoljno ispitan. U ovom radu ćemo razmotriti značaj određivanja standardnih i novih lipidnih biomarkera u cilju procene rizika za r...azvoj i progresiju DS.
Keywords:
Lipid profile / small dense LDL / HDL functionality / diabetes / lipidni status / male guste LDL čestice / funkcionalnost HDL čestica / dijabetes
TY - JOUR
AU - Vujčić, Sanja
AU - Stefanović, Tatjana
AU - Zeljković, Aleksandra
AU - Mihajlović, Marija
AU - Vekić, Jelena
PY - 2022
UR - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4187
AB - Diabetic foot (DF) is one of the most severe complications of diabetes that significantly
reduces the quality of life and survival of patients. Besides firmly established risk factors, novel
data indicate that alterations in lipid metabolism might also be implicated in the development and
progression of DF. Diabetic dyslipidemia is characterized by the atherogenic triad, consisting of
increased triglycerides (TG), decreased high-density lipoprotein cholesterol (HDL-C) levels and
the presence of small, dense low-density lipoprotein (LDL) particles. Accumulating evidence
suggests that profound hypertriglyceridemia and HDL-C reduction are common findings in
patients with diabetic neuropathy and significantly contribute to an increased risk for DF,
amputation and mortality. Small, dense LDL particles play an important role in the development
of cardiovascular complications of diabetes, but their clinical importance in patients with DF
remains to be established. In this paper, we will discuss the significance of standard and novel
lipid biomarker determination in the assessment of the risk for the development and progression
of DF.
AB - Dijabetesno stopalo (DS) je hronična komplikacija dijabetesa koja značajno pogoršava kvalitet života pacijenata i doprinosi visokoj stopi smrtnosti. Noviji podaci ukazuju da i poremećaj metabolizma lipida može biti uključen u razvoj i progresiju DS. Dislipidemija u dijabetesu se odlikuje postojanjem tzv. aterogene trijade, koju čine povišena koncentracija triglicerida (TG), snižena koncentracija HDL-holesterola (HDL-h) i prisustvo malih, gustih LDL čestica. U nedavno sprovedenim studijama utvrđeno je da izražena hipertrigliceridemija i snižena koncentracija HDL-h, koje su najčešće prisutne kod pacijenata sa dijabetesnom neuropatijom, dodatno doprinose razvoju DS, amputaciji i mortalitetu. Poznato je da male, guste LDL čestice imaju važnu ulogu u razvoju kardiovaskularnih komplikacija u dijabetesu, ali je značaj ovih čestica kod pacijenata sa DS još uvek nedovoljno ispitan. U ovom radu ćemo razmotriti značaj određivanja standardnih i novih lipidnih biomarkera u cilju procene rizika za razvoj i progresiju DS.
PB - Beograd : Savez farmaceutskih udruženja Srbije
T2 - Arhiv za farmaciju
T1 - Biomarkers of dyslipidemia in patients with diabetic foot
T1 - Biomarkeri dislipidemije kod pacijenata sa dijabetesnim stopalom
VL - 72
IS - 2
SP - 184
EP - 192
DO - 10.5937/arhfarm72-36296
ER -
@article{
author = "Vujčić, Sanja and Stefanović, Tatjana and Zeljković, Aleksandra and Mihajlović, Marija and Vekić, Jelena",
year = "2022",
abstract = "Diabetic foot (DF) is one of the most severe complications of diabetes that significantly
reduces the quality of life and survival of patients. Besides firmly established risk factors, novel
data indicate that alterations in lipid metabolism might also be implicated in the development and
progression of DF. Diabetic dyslipidemia is characterized by the atherogenic triad, consisting of
increased triglycerides (TG), decreased high-density lipoprotein cholesterol (HDL-C) levels and
the presence of small, dense low-density lipoprotein (LDL) particles. Accumulating evidence
suggests that profound hypertriglyceridemia and HDL-C reduction are common findings in
patients with diabetic neuropathy and significantly contribute to an increased risk for DF,
amputation and mortality. Small, dense LDL particles play an important role in the development
of cardiovascular complications of diabetes, but their clinical importance in patients with DF
remains to be established. In this paper, we will discuss the significance of standard and novel
lipid biomarker determination in the assessment of the risk for the development and progression
of DF., Dijabetesno stopalo (DS) je hronična komplikacija dijabetesa koja značajno pogoršava kvalitet života pacijenata i doprinosi visokoj stopi smrtnosti. Noviji podaci ukazuju da i poremećaj metabolizma lipida može biti uključen u razvoj i progresiju DS. Dislipidemija u dijabetesu se odlikuje postojanjem tzv. aterogene trijade, koju čine povišena koncentracija triglicerida (TG), snižena koncentracija HDL-holesterola (HDL-h) i prisustvo malih, gustih LDL čestica. U nedavno sprovedenim studijama utvrđeno je da izražena hipertrigliceridemija i snižena koncentracija HDL-h, koje su najčešće prisutne kod pacijenata sa dijabetesnom neuropatijom, dodatno doprinose razvoju DS, amputaciji i mortalitetu. Poznato je da male, guste LDL čestice imaju važnu ulogu u razvoju kardiovaskularnih komplikacija u dijabetesu, ali je značaj ovih čestica kod pacijenata sa DS još uvek nedovoljno ispitan. U ovom radu ćemo razmotriti značaj određivanja standardnih i novih lipidnih biomarkera u cilju procene rizika za razvoj i progresiju DS.",
publisher = "Beograd : Savez farmaceutskih udruženja Srbije",
journal = "Arhiv za farmaciju",
title = "Biomarkers of dyslipidemia in patients with diabetic foot, Biomarkeri dislipidemije kod pacijenata sa dijabetesnim stopalom",
volume = "72",
number = "2",
pages = "184-192",
doi = "10.5937/arhfarm72-36296"
}
Vujčić, S., Stefanović, T., Zeljković, A., Mihajlović, M.,& Vekić, J.. (2022). Biomarkers of dyslipidemia in patients with diabetic foot. in Arhiv za farmaciju
Beograd : Savez farmaceutskih udruženja Srbije., 72(2), 184-192.
https://doi.org/10.5937/arhfarm72-36296
Vujčić S, Stefanović T, Zeljković A, Mihajlović M, Vekić J. Biomarkers of dyslipidemia in patients with diabetic foot. in Arhiv za farmaciju. 2022;72(2):184-192.
doi:10.5937/arhfarm72-36296 .
Vujčić, Sanja, Stefanović, Tatjana, Zeljković, Aleksandra, Mihajlović, Marija, Vekić, Jelena, "Biomarkers of dyslipidemia in patients with diabetic foot" in Arhiv za farmaciju, 72, no. 2 (2022):184-192,
https://doi.org/10.5937/arhfarm72-36296 . .
